We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Profound Medical Corp | TSX:PRN | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.32 | -2.78% | 11.19 | 11.07 | 11.20 | 11.50 | 10.62 | 10.62 | 1,900 | 22:00:00 |
From May 2023 to May 2024
By Stephen Nakrosis
Shares of Profound Medical rose in post-market trading on Monday following the news that the U.S. Food and Drug Administration granted 510(k) clearance for the Thermal Boost module for use in conjunction with TULSA-PRO.
The stock rose 8.7% to $10.76 at 4:12 p.m. ET, and ended the day's regular session down less than 1% at $9.92.
TULSA-PRO can be used by surgeons to ablate prostate tissue in patients, including those with prostate cancer, the company said. The company said it is developing software modules that will work in conjunction with TULSA-PRO, covering a wide variety of prostate disease states, shapes and sizes.
Section 510(k) of the Food, Drug and Cosmetic Act requires manufacturers to give the FDA 90 days advance notice before they can market a medical device.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 25, 2023 16:46 ET (20:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Profound Medical Chart |
1 Month Profound Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
